Page last updated: 2024-11-01

o(6)-benzylguanine and Protoporphyria, Erythropoietic

o(6)-benzylguanine has been researched along with Protoporphyria, Erythropoietic in 1 studies

O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity

Protoporphyria, Erythropoietic: An autosomal dominant porphyria that is due to a deficiency of FERROCHELATASE (heme synthetase) in both the LIVER and the BONE MARROW, the last enzyme in the 8-enzyme biosynthetic pathway of HEME. Clinical features include mainly neurological symptoms, rarely cutaneous lesions, and elevated levels of protoporphyrin and COPROPORPHYRINS in the feces.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Richard, E1
Robert, E1
Cario-André, M1
Ged, C1
GĂ©ronimi, F1
Gerson, SL1
de Verneuil, H1
Moreau-Gaudry, F1

Other Studies

1 other study available for o(6)-benzylguanine and Protoporphyria, Erythropoietic

ArticleYear
Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection.
    Gene therapy, 2004, Volume: 11, Issue:22

    Topics: Animals; Antineoplastic Agents; Carmustine; Female; Ferrochelatase; Genetic Engineering; Genetic The

2004